AbbVie Inc (ABBV)vsVicarious Surgical Inc. (RBOT)
ABBV
AbbVie Inc
$227.23
-2.69%
HEALTHCARE · Cap: $380.57B
RBOT
Vicarious Surgical Inc.
$0.69
+3.78%
HEALTHCARE · Cap: $7.07M
Smart Verdict
WallStSmart Research — data-driven comparison
ABBV leads profitability with a 5.8% profit margin vs 0.0%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
RBOT
Avoid23
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-55.6%
Fair Value
$146.00
Current Price
$227.23
$81.23 premium
Intrinsic value data unavailable for RBOT.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Reasonable price relative to book value
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.
Bull Case : RBOT
The strongest argument for RBOT centers on Price/Book.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 105.1x leaves little room for execution misses.
Bear Case : RBOT
The primary concerns for RBOT are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
RBOT carries more volatility with a beta of 1.82 — expect wider price swings.
ABBV is growing revenue faster at 12.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 23/100) and 12.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Vicarious Surgical Inc.
HEALTHCARE · MEDICAL DEVICES · USA
Vicarious Surgical Inc. (RBOT) is an innovative medical technology firm that is transforming surgical procedures through its state-of-the-art robotic surgical systems. By harnessing a proprietary platform that combines advanced robotics and artificial intelligence, Vicarious Surgical pioneers minimally invasive surgery, enhancing surgeons' precision, control, and visualization. The company's commitment to improving surgical efficiency and reducing patient recovery times positions it as a key player in the expanding surgical robotics market, addressing the growing demand for effective robotic-assisted interventions in modern healthcare. With a strong focus on innovation, Vicarious Surgical is dedicated to advancing patient care and outcomes in a rapidly evolving medical landscape.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?